Molecular Partners
Business Services · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Wagistrasse 14, Schlieren, Zurich, 8952,...Phone Number
+41 447557700Website
www.molecularpartners.comRevenue
$6.2 MillionStock Symbol
MOLNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Molecular Partners
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.Explore more
Molecular Partners Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Molecular Partners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Molecular Partners has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Molecular Partners launches new products
Congratulate Masked Content for being promoted to Masked Content at Molecular Partners
Molecular Partners, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Molecular Partners has new funding data
Click to see if Molecular Partners had a recent Job posting/layoffs
Earning: See what the market has to say on Molecular Partners recently announced quarterly report
Check out if Molecular Partners is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Molecular Partners is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Molecular Partners is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Molecular Partners.
Molecular Partners financials insights
Gather financial insights about Molecular Partners, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$15.6M
2009
Series B
$44.2M
2014
Stock Offering
$108.3M
2016
Share Placement
$31.2M
Molecular Partners Tech Stack
A closer look at the technologies used by Molecular Partners
Most Recent Scoops
Event
Product Marketing, Events, Engineering, Research & Development, Contingent Workforce, Sales, Business Development, Outsourcing, Search, Bioengineering, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, HR Operations, Manufacturing Operations, Operations, Organizational Development
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Molecular Partners News & Media
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the ManageMolecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update across its pipeline of targeted alpha Radio-DARPin therapeutics (RDTs).Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners”), and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of lead-212 (212Pb) based targeted alpha therapies (TAT), today anMolecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 Americ
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Molecular Partners
Sign Up For FreeTo access detailed company insights
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious... Read More
